Get the Stockscreener App
14.26
7.91%
1.045
After Hours:
14.26
0.005
+0.04%
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus Therapeutics at Leerink’s Conference: mRNA Innovations and Strategic Plans - Investing.com UK
Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism - Markets Insider
Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group - Defense World
Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - Simply Wall St
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $60.00 - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript - Insider Monkey
Arcturus Therapeutics stock hits 52-week low at $14.3 By Investing.com - Investing.com Australia
Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock - Benzinga
Arcturus Therapeutics stock hits 52-week low at $14.3 - Investing.com India
Arcturus Therapeutics Holdings Inc to Host Earnings Call - ACCESS Newswire
Earnings call transcript: Arcturus Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com South Africa
Arcturus Therapeutics Reports Q4 2024 Earnings: EPS of ($1.11) M - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance
Arcturus Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Arcturus Therapeutics Holdings Inc earnings missed by $0.92, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Arcturus Therapeutics Q4 2024 misses estimates - Investing.com
Arcturus Therapeutics drops 7% as Q4 results disappoint - MSN
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Arcturus Therapeutics Q4 and FY 2024 Financial Update - TradingView
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (ARCT) reports earnings - Quartz
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025 - BioSpace
Arcturus Therapeutics Q4 2024 Earnings Preview - MSN
mRNA Leader Arcturus Therapeutics Set for Key Investor Presentation at Leerink Conference - StockTitan
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Repor - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Synaptics Seeks to Alter the Trajectory of the IoT at Embedded World With Contextual Edge AI and Wireless Innovations - GlobeNewswire Inc.
ARK Investment Management LLC Reduces Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (ARCT) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below 200-Day Moving AverageHere's Why - MarketBeat
Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday - Defense World
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 - Business Wire
Can This mRNA Pioneer's Q4 Earnings Show Commercial Progress? March 6 Call Details - StockTitan
Long Term Trading Analysis for (ARCT) - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Down 9.9% in January - MarketBeat
Empire Life Investments Inc. Purchases 128,771 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
HC Wainwright Reaffirms Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - MarketBeat
The week in pharma: action, reaction and insight – week to February 14 - The Pharma Letter
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $65.00 Consensus Target Price from Analysts - Defense World
HC Wainwright Reaffirms “Buy” Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
Sumitomo Mitsui Trust Group Inc. Has $35.04 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
EC approves CSL and Arcturus’ Kostaive - The Pharma Letter
CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine - Marketscreener.com
Breaking Down Arcturus Therapeutics: 5 Analysts Share Their Views - Benzinga
ARCTArcturus Therape Latest Stock News & Market Updates - StockTitan
Arcturus Therapeutics Says EU Commission Approves COVID-19 Vaccine Kostaive - Marketscreener.com
EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics - Nasdaq
Revolutionary COVID Vaccine Breakthrough: New Technology Shows Year-Long Immunity in EU Approval - StockTitan
Revolutionary COVID Vaccine Breakthrough: EU Approves KOSTAIVE with Year-Long Immunity Power - StockTitan
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - The Malaysian Reserve
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):